173 related articles for article (PubMed ID: 20813398)
1. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.
Shaw GJ; Meunier JM; Lindsell CJ; Pancioli AM; Holland CK
Thromb Res; 2010 Oct; 126(4):e305-11. PubMed ID: 20813398
[TBL] [Abstract][Full Text] [Related]
2. Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots.
Meunier JM; Holland CK; Pancioli AM; Lindsell CJ; Shaw GJ
Thromb Res; 2009; 123(3):528-36. PubMed ID: 18619651
[TBL] [Abstract][Full Text] [Related]
3. Temperature affects thrombolytic efficacy using rt-PA and eptifibatide, an in vitro study.
Meunier JM; Chang WT; Bluett B; Wenker E; Lindsell CJ; Shaw GJ
Ther Hypothermia Temp Manag; 2012 Sep; 2(3):112-8. PubMed ID: 23667777
[TBL] [Abstract][Full Text] [Related]
4. Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".
Meunier JM; Wenker E; Lindsell CJ; Shaw GJ
Acad Emerg Med; 2013 May; 20(5):449-55. PubMed ID: 23672358
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Meunier JM; Holland CK; Porter TM; Lindsell CJ; Shaw GJ
Curr Neurovasc Res; 2011 Nov; 8(4):305-12. PubMed ID: 22023612
[TBL] [Abstract][Full Text] [Related]
6. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots.
Collet JP; Montalescot G; Lesty C; Weisel JW
Circ Res; 2002 Mar; 90(4):428-34. PubMed ID: 11884372
[TBL] [Abstract][Full Text] [Related]
7. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
[TBL] [Abstract][Full Text] [Related]
8. Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
Rubenstein MH; Finn AV; Leinbach RC; Hollenbach S; Aretz HT; Virmani R; Gold HK
J Am Coll Cardiol; 2004 Jan; 43(2):287-94. PubMed ID: 14736451
[TBL] [Abstract][Full Text] [Related]
9. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
[TBL] [Abstract][Full Text] [Related]
10. Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.
Kandadai MA; Meunier J; Lindsell CJ; Shaw GJ; Elkind MS
Curr Neurovasc Res; 2012 Aug; 9(3):207-13. PubMed ID: 22621227
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes.
Shaw GJ; Meunier JM; Huang SL; Lindsell CJ; McPherson DD; Holland CK
Thromb Res; 2009 Jul; 124(3):306-10. PubMed ID: 19217651
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
[TBL] [Abstract][Full Text] [Related]
13. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.
Yoon HC; Miller FJ
AJR Am J Roentgenol; 2002 Mar; 178(3):617-22. PubMed ID: 11856686
[TBL] [Abstract][Full Text] [Related]
14. Effect of Clot Stiffness on Recombinant Tissue Plasminogen Activator Lytic Susceptibility in Vitro.
Mercado-Shekhar KP; Kleven RT; Aponte Rivera H; Lewis R; Karani KB; Vos HJ; Abruzzo TA; Haworth KJ; Holland CK
Ultrasound Med Biol; 2018 Dec; 44(12):2710-2727. PubMed ID: 30268531
[TBL] [Abstract][Full Text] [Related]
15. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
Eggers J; Ossadnik S; Hütten H; Seidel G
Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
[TBL] [Abstract][Full Text] [Related]
16. "Plasminogen steal" and clot lysis.
Torr SR; Nachowiak DA; Fujii S; Sobel BE
J Am Coll Cardiol; 1992 Apr; 19(5):1085-90. PubMed ID: 1532403
[TBL] [Abstract][Full Text] [Related]
17. Comparative lytic efficacy of rt-PA and ultrasound in porcine versus human clots.
Huang S; Shekhar H; Holland CK
PLoS One; 2017; 12(5):e0177786. PubMed ID: 28545055
[TBL] [Abstract][Full Text] [Related]
18. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
20. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
